Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association

One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better understanding of the pathophysiology of this disease are critical to optimal treatment. The "omics"-genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics- of heart...

Full description

Saved in:
Bibliographic Details
Published inCirculation. Genomic and precision medicine Vol. 12; no. 10; p. 458
Main Authors Cresci, Sharon, Pereira, Naveen L, Ahmad, Ferhaan, Byku, Mirnela, de las Fuentes, Lisa, Lanfear, David E, Reilly, Carolyn M, Owens, Anjali T, Wolf, Matthew J
Format Journal Article
LanguageEnglish
Published United States 01.10.2019
Subjects
American Heart Association
Epigenomics
Heart Failure - genetics
Heart Failure - metabolism
Heart Failure - microbiology
Heart Failure - therapy
Humans
Metabolomics
Microbiota
Precision Medicine - trends
Proteomics
United States
United States
early diagnosis
heart failure
precision medicine
preventive medicine
AHA Scientific Statements
Online AccessGet more information

Cover

More Information
Summary:One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better understanding of the pathophysiology of this disease are critical to optimal treatment. The "omics"-genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics- of heart failure represent rapidly expanding fields of science that have, to date, not been integrated into a single body of work. The goals of this statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.
ISSN:2574-8300
DOI:10.1161/hcg.0000000000000058